Clinical Trial: Clinical Study of Local and Systemic Biological Impact of GLP1/GIP-Receptor Agonists in Patients With Breast Cancer: The CLARA Trial

U.S., July 1 -- ClinicalTrials.gov registry received information related to the study (NCT07676331) titled 'Clinical Study of Local and Systemic Biological Impact of GLP1/GIP-Receptor Agonists in Patients With Breast Cancer: The CLARA Trial' on June 16.

Brief Summary: The CLARA trial is a phase II window-of-opportunity trial evaluating how a commonly used weight-loss medication (tirzepatide, a GLP-1/GIP receptor agonist) affects breast cancer biology, alone and in combination with standard hormone therapy (letrozole).

The main goal is to determine whether tirzepatide, alone or combined with letrozole, reduces tumor cell growth.

Study Start Date: Aug. 01

Study Type: INTERVENTIONAL

Condition: Hormone-receptor-positive Breast Cancer Earl...